In this exclusive Q&A, Dr Jenna Brager, Executive Vice President of Drug Development for MyMD Pharmaceuticals® explains to EPR why its oral small molecule drug could transform how TNF-α based diseases are treated.
Following her presentation on age-related disease at BioFuture 2023, Executive Vice President of Drug Development for MyMD Pharmaceuticals®, Dr Jenna Brager, shares with EPR why the company’s next-generation tumour necrosis factor (TNF)-alpha inhibitor has potential in inflammatory and autoimmune disorders. In July 2023, MyMD Pharmaceuticals released results from its Phase II study in sarcopenia evaluating potential of MYMD-1®, its first-in-class oral TNF-α inhibitor.
In this Q&A, Dr Brager highlighted that to date, “there are no oral TNF-a inhibitor drugs available on the market [and no other TNF-a inhibitor] besides MYMD-1 have reached Phase II trials yet.”
Positively, Dr Brager shared that in clinical trials, the company’s lead clinical candidate has demonstrated ability to cross the blood-brain barrier and to “not cause serious side effects common with traditional immunosuppressive therapies that treat inflammation.”
Are you looking to explore how lipid formulations in softgels can enhance drug absorption and bioavailability. Register for our upcoming webinar to find out!
3 September 2025 | 3:00 PM BST | FREE Webinar
This webinar will delve into the different types of lipid formulations, such as solutions, suspensions, emulsions, and self-(micro)emulsifying systems. Applications span diverse therapeutic areas including HIV therapy, oncology, immunosuppressants, and emerging treatments like medicinal cannabis (eg, CBD).
What You’ll Learn:
Lipid formulation development and screening tools for optimisation
Key steps in scale-up and industrialisation to ensure consistency and efficiency
Impact of lipid-based softgels on drug delivery and patient outcomes.
What are the top three trends in drug development for inflammatory and autoimmune diseases?
the top three trends in drug development for inflammatory and autoimmune diseases will continue to focus on targeted biologics, precision medicine and small molecule therapies”
I believe the top three trends in drug development for inflammatory and autoimmune diseases will continue to focus on targeted biologics, precision medicine and small molecule therapies.
Targeted biologics are drugs designed to specifically target molecules or pathways involved in the disease process. In addition, there is a growing emphasis on precision medicine, where treatments are tailored to individual patients based on their genetic and molecular profiles. Small molecule therapies will also be an area of focus for inflammatory and autoimmune diseases as these drugs are typically administered orally, making them more convenient for patients than injectable biologics. Small molecule drugs can target specific enzymes, receptors, or signaling pathways involved in the disease process.
What is the TNF-α inhibitor MYMD-1, and how does it differ from standard treatments?
MyMD’s lead clinical candidate, MYMD-1, is an orally available next-generation TNF-alpha inhibitor with the promise to provide a meaningful therapeutic solution to patients not served by current TNF-alpha inhibitors. TNF-alpha is an immune modulating cytokine whose dysregulation can lead to prolonged inflammatory responses and is known to drive disease in a range of autoimmune and inflammatory disorders.
MYMD-1 has been shown to selectively block TNF-α when it becomes overactivated in autoimmune diseases and cytokine storms, but not block it from doing its normal job of being a first responder to any routine type of moderate infection. In addition, it has not been shown to cause serious side effects common with traditional immunosuppressive therapies that treat inflammation. It is a selective, oral treatment that reduces TNF-α and inflammation and does not require infusion or injection would be a welcome advance for these populations.
To date, there are no oral TNF-a inhibitor drugs available on the market. In the past, there have been attempts to manufacture as well as attempts to design small molecule therapies directed to TNF-a, however they have not led to approved products yet. The various TNF-a inhibitors on the market currently are at different phases of development, however none besides MYMD-1 have reached Phase II trials yet.
MYMD-1, a next generation, oral selective inhibitor offers the ease of oral dosing which is a significant differentiator compared to currently available TNF-α inhibitors, all of which require delivery by injection or infusion”
MYMD-1, a next generation, oral selective inhibitor offers the ease of oral dosing which is a significant differentiator compared to currently available TNF-α inhibitors, all of which require delivery by injection or infusion. MYMD-1 has shown effectiveness in pre-clinical and clinical studies in regulating the immune system.
While currently available TNF-alpha inhibitors, all of which are biologics, have improved outcomes, not all patients respond to them, and these inhibitors come with black box warnings around the risk of serious infections leading to hospitalisation and death. MYMD-1’s ease of oral dosing is a differentiator compared to currently available TNF-α blockers, all of which require delivery by injection or infusion. No approved TNF inhibitor has ever been dosed orally.
[MYMD-1] can cross the blood-brain barrier and gain access to the central nervous system (CNS), MYMD-1 is also positioned to be a possible treatment for brain-related disorders”
In addition, since the drug can cross the blood-brain barrier and gain access to the central nervous system (CNS), MYMD-1 is also positioned to be a possible treatment for brain-related disorders. Its mechanism of action and efficacy in diseases including multiple sclerosis (MS) and thyroiditis have been studied through collaborations with several academic institutions.
What are the key findings from the recently released positive topline results from the Phase II study results for MyMD’s lead clinical candidate MYMD-1?
Statistically significant positive topline results from the Phase II study of next generation oral TNF-α Inhibitor MYMD-1 in sarcopenia showing that MYMD-1 significantly reduced serum levels of chronic inflammatory markers, met all pharmacokinetic primary endpoints, and safety and tolerability secondary endpoints across multiple doses over 28 days of treatment.
The sarcopenia study met both of its primary endpoints. MYMD-1 significantly reduced serum levels of three biomarkers:
TNF-α (P=0.008), sTNFR1 (P=0.02), and IL-6 (P=0.03) maintained appropriate plasma concentrations and parameters in pharmacokinetic evaluations
These results support the unique advantages of MYMD-1 as the first oral, selective TNF-α inhibitor and a potential future treatment option for sarcopenia and other autoimmune conditions with large markets such as rheumatoid arthritis.
MyMD plans to present the data to the US Food and Drug Administration (FDA) and intends to advance the clinical programme for MYMD-1 into Phase III either alone or through partnership.
Why is a TNF-α inhibitor promising as a first-in-class therapeutic for sarcopenia/frailty?
Sarcopenia is a condition characterised by progressive loss of muscle mass, strength, and function in older adults. It is caused by the natural aging process and can be a risk for people who have diabetes, are obese, perform little to no exercise, have a poor nutrition, or smoke.
There are no FDA-approved medications to treat sarcopenia. Currently, the condition is managed with lifestyle changes, which can include increasing physical activity, if possible, and dietary changes.
What were the two main challenges in developing the TNF-α inhibitor MYMD-1? Why?
Large scale production to ensure enough product is available for a clinical trial can be challenging. To ensure an efficient process, MyMD works closely with the contract manufacturing organisation (CMO) focusing on automation and process improvement. This allows us to stay on top of quality control. All pharmaceutical companies want to save on the cost of production, but not at the expense of quality. Quality materials, trained and capable labour, and efficient production processes are necessary for creating a finished product you are proud to market.
What major changes do you anticipate in pharmaceutical drug development in the next five years?
Over the next five years, I anticipate noticeable changes in artificial intelligence (AI) and machine learning (ML) integration in [pharmaceutical drug development]”
Over the next five years, I anticipate noticeable changes in artificial intelligence (AI) and machine learning (ML) integration. These technologies will play an increasingly prominent role as it will provide powerful tools to analyse vast datasets, predict potential drug candidates, optimise clinical trial designs, and improve drug manufacturing processes.
Additionally, I believe clinical trials will continue to adapt to more innovative trial designs, such as decentralised trials, master protocols, and adaptive trials, will expedite the clinical trial process. These approaches can enhance patient recruitment, reduce costs, and increase the efficiency of testing new drugs.
Lastly, drug development will continue to focus on collaboration across industries. Collaborative efforts between pharmaceutical companies, academic institutions, and public-private partnerships will likely increase the speed to which data-driven research is generated.
About the interviewee
Dr Jenna Brager, PhD, RN, MS, serves as the Executive Vice President of Drug Development for MyMD Pharmaceuticals®.
Prior to joining MyMD, Dr Brager served as the Director of Clinical Research and Scientific Grants for LifeBridge Health in the US, where she revised and implemented over 20 policies and procedures guiding the execution and continuation of 250+ research trials (Phase I-IV) to ensure regulatory standards and compliance were upheld.
Prior to her role with LifeBridge Health, at Johns Hopkins Hospital Dr Brager worked with MyMD’s Chief Scientific Officer, Adam Kaplin to execute clinical trials funded by Janssen to combat treatment-resistant depression using intranasal esketamine.
Dr Brager received her BS in Nursing from the University of North Florida, graduating cum laude and received her PhD from the Johns Hopkins University School of Nursing. Additionally, she received a BS and MS in Sport Administration from the University of Miami (Florida).
This website uses cookies to enable, optimise and analyse site operations, as well as to provide personalised content and allow you to connect to social media. By clicking "I agree" you consent to the use of cookies for non-essential functions and the related processing of personal data. You can adjust your cookie and associated data processing preferences at any time via our "Cookie Settings". Please view our Cookie Policy to learn more about the use of cookies on our website.
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorised as ”Necessary” are stored on your browser as they are as essential for the working of basic functionalities of the website. For our other types of cookies “Advertising & Targeting”, “Analytics” and “Performance”, these help us analyse and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these different types of cookies. But opting out of some of these cookies may have an effect on your browsing experience. You can adjust the available sliders to ‘Enabled’ or ‘Disabled’, then click ‘Save and Accept’. View our Cookie Policy page.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Cookie
Description
cookielawinfo-checkbox-advertising-targeting
The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertising & Targeting".
cookielawinfo-checkbox-analytics
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Analytics".
cookielawinfo-checkbox-necessary
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Performance".
PHPSESSID
This cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy
The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
zmember_logged
This session cookie is served by our membership/subscription system and controls whether you are able to see content which is only available to logged in users.
Performance cookies are includes cookies that deliver enhanced functionalities of the website, such as caching. These cookies do not store any personal information.
Cookie
Description
cf_ob_info
This cookie is set by Cloudflare content delivery network and, in conjunction with the cookie 'cf_use_ob', is used to determine whether it should continue serving “Always Online” until the cookie expires.
cf_use_ob
This cookie is set by Cloudflare content delivery network and is used to determine whether it should continue serving “Always Online” until the cookie expires.
free_subscription_only
This session cookie is served by our membership/subscription system and controls which types of content you are able to access.
ls_smartpush
This cookie is set by Litespeed Server and allows the server to store settings to help improve performance of the site.
one_signal_sdk_db
This cookie is set by OneSignal push notifications and is used for storing user preferences in connection with their notification permission status.
YSC
This cookie is set by Youtube and is used to track the views of embedded videos.
Analytics cookies collect information about your use of the content, and in combination with previously collected information, are used to measure, understand, and report on your usage of this website.
Cookie
Description
bcookie
This cookie is set by LinkedIn. The purpose of the cookie is to enable LinkedIn functionalities on the page.
GPS
This cookie is set by YouTube and registers a unique ID for tracking users based on their geographical location
lang
This cookie is set by LinkedIn and is used to store the language preferences of a user to serve up content in that stored language the next time user visit the website.
lidc
This cookie is set by LinkedIn and used for routing.
lissc
This cookie is set by LinkedIn share Buttons and ad tags.
vuid
We embed videos from our official Vimeo channel. When you press play, Vimeo will drop third party cookies to enable the video to play and to see how long a viewer has watched the video. This cookie does not track individuals.
wow.anonymousId
This cookie is set by Spotler and tracks an anonymous visitor ID.
wow.schedule
This cookie is set by Spotler and enables it to track the Load Balance Session Queue.
wow.session
This cookie is set by Spotler to track the Internet Information Services (IIS) session state.
wow.utmvalues
This cookie is set by Spotler and stores the UTM values for the session. UTM values are specific text strings that are appended to URLs that allow Communigator to track the URLs and the UTM values when they get clicked on.
_ga
This cookie is set by Google Analytics and is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. It stores information anonymously and assign a randomly generated number to identify unique visitors.
_gat
This cookies is set by Google Universal Analytics to throttle the request rate to limit the collection of data on high traffic sites.
_gid
This cookie is set by Google Analytics and is used to store information of how visitors use a website and helps in creating an analytics report of how the website is doing. The data collected including the number visitors, the source where they have come from, and the pages visited in an anonymous form.
Advertising and targeting cookies help us provide our visitors with relevant ads and marketing campaigns.
Cookie
Description
advanced_ads_browser_width
This cookie is set by Advanced Ads and measures the browser width.
advanced_ads_page_impressions
This cookie is set by Advanced Ads and measures the number of previous page impressions.
advanced_ads_pro_server_info
This cookie is set by Advanced Ads and sets geo-location, user role and user capabilities. It is used by cache busting in Advanced Ads Pro when the appropriate visitor conditions are used.
advanced_ads_pro_visitor_referrer
This cookie is set by Advanced Ads and sets the referrer URL.
bscookie
This cookie is a browser ID cookie set by LinkedIn share Buttons and ad tags.
IDE
This cookie is set by Google DoubleClick and stores information about how the user uses the website and any other advertisement before visiting the website. This is used to present users with ads that are relevant to them according to the user profile.
li_sugr
This cookie is set by LinkedIn and is used for tracking.
UserMatchHistory
This cookie is set by Linkedin and is used to track visitors on multiple websites, in order to present relevant advertisement based on the visitor's preferences.
VISITOR_INFO1_LIVE
This cookie is set by YouTube. Used to track the information of the embedded YouTube videos on a website.